Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

Korábbi kezelés

• Other concomitant neurological infection, i.e. toxoplasmosis, cryptococcosis, progressive multifocal leukoencephalopathy, bacterial meningitis, neuro-syphilis
• History of previous TB treatment in patients with GeneXpert MTB/RIF Ultra negative or unavailable
• Current use of drugs contraindicated with study drugs and that cannot be safely stopped
• Subjects participating in another clinical trial evaluating therapies and including an exclusion period that is still in force during the screening phase

Más betegség

• HBsAg positive or anti hepatitis C virus antibodies positive
• Allergy to study drugs or any of their components
• Uncontrolled opportunistic infection
• Moderate to severe cardiac insufficiency (NYHA classes III / IV)
• Any condition which might, in the investigator's opinion, compromise the safety of treatment and/or patient's adherence to study procedures

Laborértékek

• Asymptomatic positive cryptococcal antigen in serum
• Alanine transaminase (ALT)>5 ULN

Életkor

• For women of childbearing age: 1) Pregnancy or breastfeeding; 2) Refusal to use effective contraception to be discussed with the investigator

Egyéb

• Rifampicin-resistant TB detected by GeneXpert MTB/RIF Ultra
• Person under guardianship, or deprived of freedom by a judicial or administrative decision

• Age ≥18 years
• HIV-1 infection
• Definite or probable tuberculosis meningitis
• Standard tuberculosis meningitis treatment ≤3 days: anti TB drugs at standard doses and high-dose dexamethasone as per WHO guidelines
• Signed informed consent form by patient or relative.